IRIS
SALPINI, ROMINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.800
AS - Asia 4.115
EU - Europa 3.720
SA - Sud America 670
Continente sconosciuto - Info sul continente non disponibili 610
AF - Africa 118
OC - Oceania 90
Totale 31.123
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.559
SG - Singapore 1.885
IT - Italia 1.006
CN - Cina 772
BR - Brasile 527
RU - Federazione Russa 475
HK - Hong Kong 377
DE - Germania 361
VN - Vietnam 326
FR - Francia 265
FI - Finlandia 258
IE - Irlanda 247
SE - Svezia 233
BD - Bangladesh 207
PL - Polonia 206
UA - Ucraina 204
GB - Regno Unito 178
JP - Giappone 142
CA - Canada 125
KR - Corea 107
AU - Australia 84
IN - India 82
ES - Italia 76
NL - Olanda 63
AR - Argentina 55
MX - Messico 46
TR - Turchia 40
ID - Indonesia 36
CZ - Repubblica Ceca 34
ZA - Sudafrica 29
AT - Austria 28
JM - Giamaica 26
CO - Colombia 25
IQ - Iraq 22
EC - Ecuador 18
PH - Filippine 17
BE - Belgio 16
CH - Svizzera 16
NG - Nigeria 15
VE - Venezuela 15
MA - Marocco 14
CM - Camerun 13
AE - Emirati Arabi Uniti 12
PK - Pakistan 12
BG - Bulgaria 10
EG - Egitto 10
CL - Cile 9
CR - Costa Rica 9
HN - Honduras 9
NP - Nepal 9
KE - Kenya 8
PY - Paraguay 8
TN - Tunisia 8
DZ - Algeria 7
UZ - Uzbekistan 7
BB - Barbados 6
GT - Guatemala 6
IR - Iran 6
LT - Lituania 6
MY - Malesia 6
NZ - Nuova Zelanda 6
PE - Perù 6
PT - Portogallo 6
RO - Romania 6
SA - Arabia Saudita 6
DK - Danimarca 5
EU - Europa 5
JO - Giordania 5
KZ - Kazakistan 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
IL - Israele 4
NI - Nicaragua 4
TH - Thailandia 4
UY - Uruguay 4
EE - Estonia 3
GR - Grecia 3
KH - Cambogia 3
LK - Sri Lanka 3
MN - Mongolia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BO - Bolivia 2
CG - Congo 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HU - Ungheria 2
KG - Kirghizistan 2
OM - Oman 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UG - Uganda 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 30.506
Salva come PNG Salva come JPEG
Città #
Wilmington 4.617
Woodbridge 4.351
Houston 3.881
Singapore 1.136
San Jose 772
Ashburn 764
Fairfield 738
Chandler 487
Ann Arbor 385
Hong Kong 371
Rome 299
Council Bluffs 298
Beijing 296
Seattle 279
New York 260
Cambridge 240
Dublin 208
Helsinki 196
Los Angeles 182
Santa Clara 181
Jacksonville 162
Kraków 157
The Dalles 151
Medford 136
Tokyo 125
Milan 121
Dearborn 101
Ho Chi Minh City 99
Hanoi 89
Buffalo 87
Munich 78
Dallas 75
Denver 75
Lawrence 66
Moscow 58
San Diego 58
Nuremberg 57
São Paulo 57
Chicago 52
Lauterbourg 52
Orem 45
Boardman 44
London 44
Menlo Park 39
Naples 34
Toronto 33
Warsaw 33
Montreal 32
San Francisco 32
Brooklyn 31
Phoenix 31
Atlanta 30
Melbourne 30
Sydney 30
Zhengzhou 30
Stockholm 28
Chennai 27
La Veta 27
Mülheim 27
North Bergen 27
Jakarta 24
Redondo Beach 24
Creede 22
Palo Alto 22
Johannesburg 21
Poplar 21
Washington 21
Amsterdam 19
Canberra 19
Frankfurt am Main 19
Brno 18
Columbus 18
Madrid 18
Brasília 17
Lappeenranta 17
Mexico City 17
Verona 17
Bari 16
Boston 16
Engelhard 16
Guangzhou 16
Haiphong 16
Palermo 16
Vienna 16
Brussels 15
Cedarhurst 15
North Charleston 15
Seoul 15
Shanghai 15
Colorado Springs 14
Genoa 14
Manchester 14
Olomouc 14
Redwood City 14
Barcelona 13
Kingston 13
Paris 13
Falls Church 12
Florence 12
Pittsburgh 12
Totale 23.117
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 593
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 527
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 525
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 503
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 499
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 499
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 498
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 491
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 484
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 483
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 477
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 475
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 469
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 467
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 461
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 460
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 455
Molecular analysis of hepatitis B virus in Bulgaria 450
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 440
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 440
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 439
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 438
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 437
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 435
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 433
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 433
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 427
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 426
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 426
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 424
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 424
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 420
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 419
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy 415
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 414
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 407
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 402
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 392
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 391
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 384
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 377
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 351
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis 335
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 307
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 288
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 279
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 272
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe 269
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 262
Different patterns of HIV-1 replication in MACROPHAGES is led by co-receptor usage 247
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 235
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 231
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 225
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 221
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 202
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 201
Reliable timescale inference of HBV genotype A origin and phylodynamics 195
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 191
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 188
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 181
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 175
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 170
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 166
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 165
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 153
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 150
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 138
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 138
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 137
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 129
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 124
SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays 124
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 123
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection. 121
Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients 120
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 117
Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection 117
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 117
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 116
First National Prevalence in Italian Horse Population and Phylogenesis Highlight a Fourth Sub-Type Candidate of Equine Hepacivirus 115
Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome. 113
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 110
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 110
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 107
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 106
Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach 106
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach 106
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses 105
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs 104
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 103
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 103
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 102
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 101
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 100
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 99
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 99
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 98
Detecting hepatitis B viral amino acid sequence mutations in occult hepatitis B infections via bayesian partition model 95
Amino acid variability of small molecule inhibitors and mAbs target sites in globally circulating RSV strains 94
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles 94
Totale 27.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022825 0 0 0 43 34 86 54 35 289 49 27 208
2022/20231.272 120 114 103 139 122 238 87 106 104 16 98 25
2023/2024910 163 26 95 50 90 143 44 17 57 83 21 121
2024/20253.066 110 583 306 213 127 235 336 174 346 218 209 209
2025/20266.389 568 252 556 549 591 296 839 764 748 583 315 328
2026/20272.303 381 389 1.098 435 0 0 0 0 0 0 0 0
Totale 31.123